<DOC>
	<DOCNO>NCT00559845</DOCNO>
	<brief_summary>This single arm study ass efficacy safety sequential neoadjuvant chemotherapy Avastin , surgery and/or radiotherapy , patient inflammatory locally advanced operable breast cancer . Patients receive FEC , follow paclitaxel , give concomitantly Avastin ( 10mg/kg i.v . every 2 week ) . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Patients With Inflammatory Locally Advanced Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>female patient , &gt; =18 year age ; stage III , inflammatory breast cancer ; ER/PgR positive negative HER2 negative ; normal LVEF . previous chemotherapy/endocrine therapy ; evidence distant metastatic disease ; primary tumor last 5 year ( except adequately treated cancer situ cervix , basal cell skin cancer ) ; chronic daily treatment &gt; 325mg/day aspirin , &gt; 75mg/day clopidogrel .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>